Research Analysts Set Expectations for VERA FY2025 Earnings

Vera Therapeutics, Inc. (NASDAQ:VERA) – Investment analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Vera Therapeutics in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst P. Stavropoulos expects that the company will earn ($2.22) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $107.00 target price on the stock. The consensus estimate for Vera Therapeutics’ current full-year earnings is ($2.89) per share.

A number of other equities analysts have also recently issued reports on the stock. Guggenheim increased their price objective on shares of Vera Therapeutics from $56.00 to $64.00 and gave the stock a “buy” rating in a research report on Monday, October 28th. Scotiabank assumed coverage on Vera Therapeutics in a research note on Wednesday, October 16th. They set a “sector outperform” rating and a $60.00 price target on the stock. Wedbush raised their price objective on Vera Therapeutics from $30.00 to $38.00 and gave the company a “neutral” rating in a research note on Friday, November 8th. Wells Fargo & Company started coverage on Vera Therapeutics in a research report on Thursday, November 21st. They set an “overweight” rating and a $70.00 target price on the stock. Finally, JPMorgan Chase & Co. lifted their price target on shares of Vera Therapeutics from $72.00 to $75.00 and gave the company an “overweight” rating in a research report on Tuesday, November 5th. One analyst has rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $63.50.

Vera Therapeutics Stock Performance

VERA stock opened at $34.09 on Thursday. The firm has a market cap of $2.16 billion, a PE ratio of -13.06 and a beta of 1.15. The stock has a 50-day moving average price of $42.82 and a 200-day moving average price of $40.88. The company has a current ratio of 13.76, a quick ratio of 13.76 and a debt-to-equity ratio of 0.17. Vera Therapeutics has a 1-year low of $16.84 and a 1-year high of $51.61.

Vera Therapeutics (NASDAQ:VERA) last released its earnings results on Thursday, November 7th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($0.21).

Institutional Trading of Vera Therapeutics

A number of hedge funds have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. boosted its stake in Vera Therapeutics by 21.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,983 shares of the company’s stock worth $86,000 after acquiring an additional 350 shares in the last quarter. KBC Group NV lifted its holdings in shares of Vera Therapeutics by 127.2% during the fourth quarter. KBC Group NV now owns 2,477 shares of the company’s stock valued at $105,000 after purchasing an additional 1,387 shares during the last quarter. Ensign Peak Advisors Inc boosted its position in shares of Vera Therapeutics by 13.5% in the 2nd quarter. Ensign Peak Advisors Inc now owns 11,750 shares of the company’s stock worth $425,000 after purchasing an additional 1,400 shares in the last quarter. Handelsbanken Fonder AB grew its stake in shares of Vera Therapeutics by 19.0% in the 3rd quarter. Handelsbanken Fonder AB now owns 13,800 shares of the company’s stock worth $610,000 after buying an additional 2,200 shares during the last quarter. Finally, Point72 DIFC Ltd grew its stake in shares of Vera Therapeutics by 8.4% in the 3rd quarter. Point72 DIFC Ltd now owns 43,789 shares of the company’s stock worth $1,935,000 after buying an additional 3,376 shares during the last quarter. Institutional investors own 99.21% of the company’s stock.

Insider Activity

In other Vera Therapeutics news, Director Beth C. Seidenberg sold 15,000 shares of the business’s stock in a transaction on Monday, October 28th. The shares were sold at an average price of $48.03, for a total transaction of $720,450.00. Following the transaction, the director now directly owns 131,553 shares of the company’s stock, valued at approximately $6,318,490.59. The trade was a 10.24 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Marshall Fordyce sold 17,500 shares of Vera Therapeutics stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $46.94, for a total transaction of $821,450.00. Following the sale, the chief executive officer now directly owns 85,942 shares in the company, valued at $4,034,117.48. The trade was a 16.92 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 67,500 shares of company stock valued at $3,026,075. 21.70% of the stock is currently owned by insiders.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.